Mitotane | 2,4′-DDD;o,p'-DDD;Lisodren.;Mytotan;Khloditan;Chlodithane;DDD, Chloditan;WR13045;CB313;NSC 38721;1,1-Dichlorodiphenildichloroethane | 米托坦 | Insecticide

Mitotane/米托坦 {[allProObj[0].p_purity_real_show]}

货号：A817688 同义名： 2,4′-DDD; o,p'-DDD

Mitotane 是一种甾体生成抑制剂，通过诱导细胞内胆固醇积累引发脂毒性，抑制肾上腺皮质功能，并激活 CYP3A4 基因表达，表现出显著的抗肿瘤作用，常用于研究肾上腺皮质癌及库欣综合征。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Mitotane/米托坦化学结构
CAS号：53-19-0

Mitotane/米托坦 3D分子结构
CAS号：53-19-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Mitotane/米托坦生物活性

描述

Mitotane is a steroidogenesis inhibitor and cytostatic antineoplastic medication which is used in the treatment of adrenocortical carcinoma and Cushing's syndrome. In the AtT20/D16v-F2 cell line and in primary cultures, mitotane reduces cell viability by inducing caspase-mediated apoptosis and reduces ACTH secretion. In the AtT20/D16v-F2 cell line, mitotane reduces Pomc expression and blocks the stimulatory effects of corticotropin-releasing hormone on cell viability, ACTH secretion, and Pomc expression^[3]. Among the oxysterols detected in mitotane-treated cells, 27OHC was markedly produced, as well as lanosterol and lathosterol cholesterol precursors. In this cell model, mitotane was confirmed to affect mitochondrial transmembrane potential and induce apoptosis. Such cytotoxic effects were perfectly matched by H295R cell treatment with a single identical micromolar amount of 27OHC^[4]. Treatment with mitotane (50 µM for 24 h) decreased the viability of FTC‑133, BCPAP, SW1736, C643 and TT cells by 12, 59, 54, 31 and 66%, respectively. Mitotane elicited pleiotropic effects on TC (thyroid cancer) cells, including induction of ER (endoplasmic reticulum) stress, inhibition of mitochondrial membrane potential and induction of apoptosis^[5]. In addition, low-dose mitotane can trigger neurological and endocrinological complications in a pediatric patient; the drug dose should be individualized with frequent monitoring of the therapeutic level^[6].

Mitotane/米托坦细胞实验

Cell Line NCI-H295R cells NCI-H295R cells NCI-H295R cells TT cells C643 cells SW1736 cells BCPAP cells FTC-133 cells ACC-T36 cells H295R cells H295R cells GM00038 NCI-H295R	Concentration	Treated Time	Description	References
NCI-H295R cells	50μM	6 hours	Mitotane-induced necrosis was not inhibited by caspase inhibitors zVAD or emricasan, indicating a non-apoptotic necrotic cell death.	Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22269-22274
NCI-H295R cells	50μM	6 hours	Mitotane induces non-apoptotic necrotic cell death, with membrane blebbing and SYTOX positivity occurring within 6 hours. The pan-caspase inhibitor zVAD-fmk prevented membrane blebbing but did not inhibit SYTOX positivity.	Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22269-22274
NCI-H295R cells	50 µM	6 hours	Investigation of mitotane-induced cell death, finding that vPIF-1 or human insulin did not reverse this necrosis, while ITS-1 partially protected the cells	Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2300320120
TT cells	50 µM	24 hours	Treatment with mitotane (50 µM for 24 h) decreased the viability of TT cells by 66%.	Int J Oncol. 2019 Jul;55(1):7-20
C643 cells	50 µM	24 hours	Treatment with mitotane (50 µM for 24 h) decreased the viability of C643 cells by 31%.	Int J Oncol. 2019 Jul;55(1):7-20
SW1736 cells	50 µM	24 hours	Treatment with mitotane (50 µM for 24 h) decreased the viability of SW1736 cells by 54%.	Int J Oncol. 2019 Jul;55(1):7-20
BCPAP cells	50 µM	24 hours	Treatment with mitotane (50 µM for 24 h) decreased the viability of BCPAP cells by 59%.	Int J Oncol. 2019 Jul;55(1):7-20
FTC-133 cells	50 µM	24 hours	Treatment with mitotane (50 µM for 24 h) decreased the viability of FTC-133 cells by 12%.	Int J Oncol. 2019 Jul;55(1):7-20
ACC-T36 cells	10, 30 µM	72 hours	Evaluate the effect of mitotane on cell viability in spheroid cultures of ACC-T36 cells. Results showed that 30 µM mitotane reduced cell viability by 40%.	Cancer Cell Int. 2018 Mar 1;18:29
H295R cells	10, 30, 50 µM	72 hours	Evaluate the effect of mitotane on cell viability in monolayer and spheroid cultures of H295R cells. Results showed that in monolayer culture, 30 and 50 µM mitotane reduced cell viability by 86.9% and 98.4%, respectively, while in spheroid culture, the reduction was only 15.4% and 26.4%.	Cancer Cell Int. 2018 Mar 1;18:29
H295R cells	5 or 10 µM	24, 48 or 72 hours	To evaluate the effect of Mitotane on cholesterol precursors and oxysterol profiles, results showed that Mitotane significantly increased the content of 27OHC and affected the cholesterol synthesis pathway.	Cells. 2020 Apr 4;9(4):885
GM00038	1–200 µM	24 h and 72 h	Assess the tolerability of mitotane nanocarriers in non-malignant human dermal fibroblasts. BSA-MT showed cell viability of 79±3% at 200 µM after 24 h and 82±5% after 72 h. DOPC-MT exhibited no cytotoxicity at all concentrations.	Pharmaceutics. 2022 Sep 7;14(9):1891
NCI-H295R	1–200 µM	24 h and 72 h	Evaluate the cytotoxicity of mitotane nanocarriers on adrenocortical carcinoma cells. BSA-MT reduced cell viability to 59±6% at 200 µM after 24 h and to 22±1% after 72 h. DOPC-MT had minimal impact on cell viability at the same concentration.	Pharmaceutics. 2022 Sep 7;14(9):1891

Cell Line

Concentration

Treated Time

Description

References

NCI-H295R cells

50μM

6 hours

Mitotane-induced necrosis was not inhibited by caspase inhibitors zVAD or emricasan, indicating a non-apoptotic necrotic cell death.

Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22269-22274

NCI-H295R cells

50μM

6 hours

Mitotane induces non-apoptotic necrotic cell death, with membrane blebbing and SYTOX positivity occurring within 6 hours. The pan-caspase inhibitor zVAD-fmk prevented membrane blebbing but did not inhibit SYTOX positivity.

Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22269-22274

NCI-H295R cells

50 µM

6 hours

Investigation of mitotane-induced cell death, finding that vPIF-1 or human insulin did not reverse this necrosis, while ITS-1 partially protected the cells

Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2300320120

TT cells

50 µM

24 hours

Treatment with mitotane (50 µM for 24 h) decreased the viability of TT cells by 66%.